We have previously shown that hSef downregulation enhances FGF signalling in prostate cancer cells and evidence of loss of transcript expression in high-grade and metastatic clinical disease in a pilot cohort of patients (Darby et al, 2006). Here, IL17RD is linked to prostate carcinoma.